• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

byKassandra McFarlaneandSamuel Chan
February 22, 2022
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Cancer biosimilar treatment trials have clinical outcomes that do not differ statistically from reference biologic products

2. The design elements of clinical trials for biosimilar drugs are rigorous

Evidence Rating Level: 1 (Excellent)

Study Rundown: Biologic treatments constitute a large portion of prescription costs in the United States. Biosimilar drugs are intended to reduce costs but are required to undergo stringent testing before approval. This systematic review and meta-analysis aimed to compare the study design of cancer biosimilar efficacy trials with reference drug trials on measures of population size, randomization and blinding. The effectiveness of biosimilars was compared with the biologic drugs as well. Reference drug trials had a lower mean number of patients than biosimilar studies (302 compared to 397, respectively). Biosimilar studies were randomized clinical trials (RCTs) more often than were reference drug trials (100% vs. 50%, respectively). As well, they were more likely to be double-blinded; 84% of biosimilar trials, compared to 17% of reference drug trials. Six disease settings were explored to determine the efficacy of biosimilar drugs compared to biologics: non-small cell lung cancer, metastatic colorectal cancer (mCRC), ERBB2-positive early breast cancer, ERBB2-positive metastatic breast cancer, follicular lymphoma, and diffuse large B-cell lymphoma (DLBCL). Outcomes showed similar efficacy between biosimilars and their biologic originators in all settings. Limitations of this study include the inability to recover complete publications for several of the trials in the sample. Additionally, because the study was comparing biologics with biosimilars, there were only 3 products available (bevacizumab, trastuzumab, and rituximab). This study only explored the efficacy of biosimilars and did not include other measures, such as toxicity or immunogenicity. As such, care should be taken when interpreting the results. Overall, the clinical outcomes did not differ statistically from the reference biologic products based on efficacy.

Click to read the study in JAMA Oncology

Click to read an accompanying editorial in JAMA Oncology

Relevant Reading: Biosimilars in oncology in the United States: a review

RELATED REPORTS

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

In-Depth [meta-analysis]:This systematic review and meta-analysis included 31 cancer biosimilar trials on 3 reference products with a total of 12,310 patients. Six reference drug trials with 1,811 patients were also included as a comparison. The design elements explored included population size, randomization, and blinding of the studies. Biosimilar trials had a greater average number of patients (397) compared to reference biologic trials (302). Additionally, trials for biosimilars were both more likely to be RCTs (100% vs. 50%) and double-blinded (84% vs. 17%) than reference biologic studies. The overall response rate (ORR) of bevacizumab biosimilar vs. the biologic was 1.02 (95% confidence interval (CI), 0.94-1.10) for non-small cell lung cancer (NSCLC) and 0.95 (95% CI, 0.72-1.24) for metastatic colorectal cancer (mCRC). The ORR of trastuzumab biosimilar vs. the biologic was 1.01 (95%, 0.94-1.08) for ERBB2-positive metastatic breast cancer. The ORR of rituximab biosimilar vs. the biologic was 1.04 (95% CI, 1.00-1.08) for follicular lymphoma (FL), 1.01 (95% CI, 0.96-1.05) for diffuse large B-cell lymphoma, and 0.99 (95% CI, 0.81-1.22) for chronic lymphocytic leukemia. The meta-analysis revealed the effectiveness of biosimilars was statistically comparable to the biologic drugs for all three reference products (bevacizumab, trastuzumab, and rituximab).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bevacizumabbiosimilarsrituximabtrastuzumab
Previous Post

COVID-19 increased mortality disaster in Switzerland, Sweden, and Spain

Next Post

Maternal BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination is not associated with adverse neonatal or early infant outcomes  

RelatedReports

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers
StudyGraphics

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

April 27, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer
StudyGraphics

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

April 5, 2022
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Chronic Disease

Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression

March 29, 2022
Next Post
Compliance-linked incentives increase infant immunizations rates in rural India

Maternal BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination is not associated with adverse neonatal or early infant outcomes  

5-FU a promising treatment for CIN-2

Cervical intraepithelial neoplasia grade 3 associated with adverse pregnancy outcomes

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • University students perceive that Instagram improves social connection but impairs mental wellbeing
  • 2 Minute Medicine Rewind May 22nd, 2022
  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.